Zhejiang Hisun Pharmaceutical Co (SHSE:600267) Moat Score: 0/10 (As of Jul. 28, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600267 Zhejiang Hisun Pharmaceutical Co Ltd SHSE:600267
58 GF Score
Price ¥11.72
GF Value ¥8.85
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Zhejiang Hisun Pharmaceutical Co Moat Score?

Zhejiang Hisun Pharmaceutical Co has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Zhejiang Hisun Pharmaceutical Co has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Zhejiang Hisun Pharmaceutical Co might have No Moat - No discernible moat.

Zhejiang Hisun Pharmaceutical Co  (SHSE:600267) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Zhejiang Hisun Pharmaceutical Co Moat Score Related Terms

SHSE:600267
58GF Score
Zhejiang Hisun Pharmaceutical Co Ltd SHSE:600267
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zhejiang Hisun Pharmaceutical Co (SHSE:600267) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang Hisun Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥11.72 is trading 32.4% above its estimated GF Value™ of ¥8.85. GuruFocus considers Zhejiang Hisun Pharmaceutical Co to be Significantly Overvalued.

Key valuation signals for SHSE:600267:

  • Moat Score: 0
  • GF Value™: ¥8.85 vs. price of ¥11.72 (32.4% above fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the SHSE:600267 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zhejiang Hisun Pharmaceutical Co Business Description

Address No. 46 Waisha Road, Jiaojiang District, Zhejiang Province, Taizhou, CHN, 318000
Zhejiang Hisun Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is focused on the research, development, and distribution of pharmaceuticals. It produces and supplies antibiotics and anticancer drugs. The company's research channels cover indications like anticancer, cardiovascular, anti-infective, anti-parasitic, immunosuppressant and others. Its product portfolio includes active pharmaceutical ingredients like Anastrozole, Docetaxel, Methotrexate, and others and finished dosages such as letrozole tablets, anastrozole tablets, injection mitomycin, and others.
58GF Score

Get the complete analysis for SHSE:600267

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥11.72
Price
¥8.85
GF Value